Navigation Links
OrbusNeich's Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
Date:12/2/2010

HONG KONG, Dec. 2, 2010 /PRNewswire/ -- OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis.

The cumulative rate of the study's primary endpoint, the composite of cardiac death, myocardial infarction (MI) or target lesion revascularization (TLR) at one year follow-up, was 12.4% in patients treated with a Genous Stent, a 30% reduction compared to 17.2% for the control group treated with BMS.  The definite or probable stent thrombosis (ST) rate was 1.7% for the Genous Stent patient group, compared to 3.4% for the BMS treated patient group.

"Interventional cardiologists continue to be challenged by the 15 to 20% of all percutaneous coronary interventions that involve coronary artery bifurcation lesions," said Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, the lead author of the paper. "The results of this large study of provisional T-stenting using the Genous Stent are extremely encouraging. The endothelial progenitor cell capture stent provides an excellent alternative to bare metal stents for the treatment of these challenging lesions."

The paper, titled "One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent," is based on a single-center, non-randomized study. The study involved 178 consecutive patients who underwent percutaneous coronary intervention for a de novo bifurcation lesion treated with a Genous Stent and 465 consecutive patients treated with BMS.

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
2. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
3. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
4. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
5. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
6. Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent
9. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
10. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
11. Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lvsz93/telemedicine_and ... "Telemedicine and Mobile Healthcare Solutions, Services, and Devices: ... report to their offering. Telemedicine, ... that pertain to the use of telecommunications and ... healthcare services. They form the ecosystem that contains ...
(Date:3/3/2015)...  Cyberonics, Inc. (NASDAQ: CYBX ), a ... management of epilepsy, today announced it will participate in ... 2015, in Miami . ... Officer, will speak at 1:05 PM Eastern Time.  The ... and no formal materials will be presented.  A live ...
(Date:3/3/2015)... , March 3, 2015 Today, ... effort sponsored by America,s biopharmaceutical research companies, unveiled ... and functionality to provide patients and caregivers with ... 475 public and private patient assistance programs. ... has provided a platform to engage, educate and ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 2
... 5, 2011 Sean Reyngoudt, the world,s only amputee professional ... action-adventure series, "Catching Air", premiering Thursday, Jan. 6 on the ... at 9 p.m. through Feb. 17th. Using the ... 27-year-old Reyngoudt will be following the wind as it whistles ...
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ... the semiconductor capital equipment, medical device, energy, research, and ... Chief Executive Officer, and Casey Eichler, Chief Financial Officer, ... presentation will take place at the New York Palace ...
Cached Medicine Technology:Discovery Channel to Feature World's Only Amputee Kiteboarder 2
(Date:3/3/2015)... BC (PRWEB) March 03, 2015 ... Research ( http://www.idataresearch.com ), market saturation has made ... care in the United States. Unit sales growth ... to increase as facilities replace older systems, and ... navigation system market is very much a replacement ...
(Date:3/3/2015)... Presale tickets for Madonna will be ready for ... on March 9, with Madonna tour tickets expected to sell ... the talented artist is a significant one for fans, and ... Ticketability.com to browse the inventory of Madonna tickets ... to enjoy, the 2015 tour is expected to attract attention ...
(Date:3/3/2015)... NY (PRWEB) March 03, 2015 Ticket Down ... for her 2015 tour. This well-known ticket exchange ... savings. , Arguably the biggest name in the music business ... Madonna performs on the “Rebel Heart Tour.” Madonna, fresh off ... will kick off her latest tour on August 29th in ...
(Date:3/3/2015)... FL (PRWEB) March 03, 2015 ... be an international keynote presenter at the third ... the Melbourne Convention and Exhibition Centre March 10-12. ... Wednesday, March 11, at 11 am (Melbourne time). ... and Interests,” will discuss making each customer’s experience ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 A newly ... type I diabetes, type II diabetes, and pre-diabetes. As ... Days offers a way for diabetes sufferers to reverse ... pharmaceutical drugs. , In 2013, the U.S. diabetes ... These pharmaceutical treatments often include the use of insulin ...
Breaking Medicine News(10 mins):Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 2Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 3Health News:Presale Tickets for Madonna: Ticketability.com Announces Madonna Tour Tickets for Sale at Reduced Prices for the Rebel Heart Tour During Presales 2Health News:Cheap Madonna Tickets: Madonna Presale Tickets in Miami, New York, Brooklyn, Chicago, San Jose, Toronto, Edmonton & Vancouver Now Available at TicketDown.com 2Health News:Cheap Madonna Tickets: Madonna Presale Tickets in Miami, New York, Brooklyn, Chicago, San Jose, Toronto, Edmonton & Vancouver Now Available at TicketDown.com 3Health News:South Florida-based PureFormulas will discuss personalization at ecommerce Conference and Expo in Melbourne, Australia 2Health News:New Breakthrough In Diabetes Reaserch Show Scientifically Proven Way To Reverse Your Diabetes Naturally In 30 Short Days 2
... Two consumer,groups said today that they will continue ... cells held by the Wisconsin Alumni,Research Foundation (WARF) ... amended claims in one of the disputed patents., ... (FTCR) and the Public,Patent Foundation (PUBPAT) said they ...
... 28 Anthem Blue Cross and Blue,Shield,s Member ... BlueWorks(R),winner. A program of the Blue Cross and ... Cross and Blue Shield companies are,working to increase ... Harvard Medical School Department of Health Care Policy,evaluates ...
... physicians and clinical staff will provide needed tools to help ... obesity ... at the forefront of,today,s health concerns, Anthem Blue Cross and Blue ... they will be,hosting trainings for both physicians and clinicians to identify, ...
... Enhanced Image Quality, Customization ... and Workflow Benefits to Mammography Centers, ... an industry-leading provider of Computer-Aided Detection (CAD),solutions for ... of the TotalLook MammoAdvantage system which converts prior,mammography ...
... problems, experts say. , , THURSDAY, Feb. 28 (HealthDay ... have twice the risk of dying from heart attack ... disease is the most common cause of untreatable blindness ... center of the retina at the back of the ...
... Procter &,Gamble will donate a liter of clean and purified filtered ... ... throughout,the country this weekend over 50 million consumers will find a ... Procter & Gamble,(NYSE: PG ) products. For every P&G brandSAVER ...
Cached Medicine News:Health News:Consumer Groups Will Continue to Press Stem Cell Patent Challenge 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 3Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 3Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 3Health News:Age-Related Macular Degeneration Doubles Heart Attack and Stroke Risk 2Health News:Age-Related Macular Degeneration Doubles Heart Attack and Stroke Risk 3Health News:It's PUR & Simple: Save Money, Improve Lives 2Health News:It's PUR & Simple: Save Money, Improve Lives 3
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
... Tendril SDX is one ... pacing leads. Implantable with a ... reduced body diameter is designed ... venous obstruction and allow introduction ...
Medicine Products: